Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Spasic, Jelena; Cavic, Milena; Stanic, Nemanja; Zaric, Bojan; Kovacevic, Tomi; Radosavljevic, Davorin; Nagorni-Obradovic, Ljudmila

Spasic, Jelena; Cavic, Milena; Stanic, Nemanja; Zaric, Bojan; Kovacevic, Tomi; Radosavljevic, Davorin; Nagorni-Obradovic, Ljudmila.

Afiliação

Spasic J; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Serbia.
Cavic M; Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Serbia.
Stanic N; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Serbia.
Zaric B; Faculty of Medicine, University of Novi Sad, Serbia.
Kovacevic T; Institute for Pulmonary Diseases of Vojvodina, Serbia.
Radosavljevic D; Faculty of Medicine, University of Novi Sad, Serbia.
Nagorni-Obradovic L; Institute for Pulmonary Diseases of Vojvodina, Serbia.

Dose Response ; 20(2): 15593258221111666, 2022.

Article em En | MEDLINE | ID: mdl-35783235

Palavras-chave

RAD51; TP53; XRCC1; lung adenocarcinoma; single nucleotide polymorphism

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Dose Response Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google